Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice

References

• BrusselleGPriceDGruffydd-JonesKThe inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UKInt J Chron Obstruct Pulmon Dis2015102207221726527869
   PubMed Web of Science ®Google Scholar
• JochmannANeubauerFMiedingerDSchafrothSTammMLeuppiJDGeneral practitioner’s adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort StudySwiss Med Wkly Epub 2010 Apr 21
   Google Scholar
• LucasAESmeenkFWSmeeleIJvan SchayckCPOvertreatment with inhaled corticosteroids and diagnostic problems in primary care patients, an exploratory studyFam Pract2008252869118304973
   PubMed Web of Science ®Google Scholar
• KaplanAGApplying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practiceInt J Chron Obstruct Pulmon Dis2015102535254826648711
   PubMed Web of Science ®Google Scholar
• CalverleyPPauwelsRVestboJCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet2003361935644945612583942
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRIndacaterol-glycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• SinghDPapiACorradiMSingle inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trialLancet20163881004896397327598678
   PubMed Web of Science ®Google Scholar
• LipsonDABarnacleHBirkRFULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2017196443844628375647
   PubMed Web of Science ®Google Scholar
• TashkinDPTaubeCTriple therapy for chronic obstructive pulmonary disease management. Are our expectations fulfilled?Am J Respir Crit Care Med2017196440240428809512
   PubMed Web of Science ®Google Scholar
• PapiAVestboJFabbriLExtrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trialLancet2018391101251076108429429593
   PubMed Web of Science ®Google Scholar
• LipsonDABarnhartFBrealeyNOnce-daily single-inhaler triple versus dual therapy in patients with COPDN Engl J Med2018378181671168029668352
   PubMed Web of Science ®Google Scholar
• SuissaSDrazenJMMaking sense of triple inhaled therapy for COPDN Engl J Med2018378181723172429669218
   PubMed Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
   PubMed Web of Science ®Google Scholar
• CalverleyPMTetzlaffKVogelmeierCEosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med201719691219122128306321
   PubMed Web of Science ®Google Scholar
• WatzHTetzlaffKWoutersEFBlood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trialLancet Respir Med20164539039827066739
   PubMed Web of Science ®Google Scholar
• PascoeSLocantoreNDransfieldMTBarnesNCPavordIDBlood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trialsLancet Respir Med20153643544225878028
   PubMed Web of Science ®Google Scholar
• PavordIDLettisSLocantoreNBlood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPDThorax201671211812526585525
   PubMed Web of Science ®Google Scholar
• SiddiquiSHGuasconiAVestboJBlood eosinophils: a bio-marker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2015192452352526051430
   PubMed Web of Science ®Google Scholar
• CataldoDCorhayJLDeromEA Belgian survey on the diagnosis of asthma-COPD overlap syndromeInt J Chron Obstruct Pulmon Dis20171260161328243078
   PubMed Web of Science ®Google Scholar
• VestboJPapiACorradiMSingle inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trialLancet2017389100821919192928385353
   PubMed Web of Science ®Google Scholar
• GOLDGlobal Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2017 Report)Global Initiative for Chronic Obstructive Lung Disease, Inc.2017
   Google Scholar
• WhitePThorntonHPinnockHGeorgopoulouSBoothHPOvertreatment of COPD with inhaled corticosteroids – implications for safety and costs: cross-sectional observational studyPLoS One2013810e7522124194824
   PubMed Web of Science ®Google Scholar
• YangIAClarkeMSSimEHInhaled corticosteroids for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev20127CD00299122786484
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyPharmacovigilance Risk Assessment Committee (PRAC): inhaled corticosteroids (ICS) containing medicinal products indicated in the treatment of chronic obstructive pulmonary disease (COPD)Assessment Report EMA/330021/20162016
   Google Scholar
• VestboJAndersonJABrookRDFluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trialLancet2016387100301817182627203508
   PubMed Web of Science ®Google Scholar
• SuissaSCoulombeJErnstPDiscontinuation of inhaled corticosteroids in COPD and the risk reduction of pneumoniaChest201514851177118326110239
   PubMed Web of Science ®Google Scholar
• MiravitllesMCosioBGArnedilloAA proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary diseaseRespir Res201718119829183382
   PubMed Web of Science ®Google Scholar
• BarrechegurenMEsquinasCMiravitllesMThe asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challengesCurr Opin Pulm Med2015211747925405671
   PubMed Web of Science ®Google Scholar
• KestenSRebuckASIs the short-term response to inhaled beta-adrenergic agonist sensitive or specific for distinguishing between asthma and COPD?Chest19941054104210458162722
   PubMed Web of Science ®Google Scholar
• MiravitllesMSoler-CatalunaJJCalleMA new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC)Prim Care Respir J201322111712123443227
   PubMedGoogle Scholar
• Global Initiative for AsthmaDiagnosis of Diseases of Chronic Airflow Limitation: Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS)A Joint Project of GINA and GOLD2015 Available from: http://ginasthma.org/asthma-copd-and-asthma-copd-overlap-syndrome-acos/
   Google Scholar
• BafadhelMPavordIDRussellREKEosinophils in COPD: just another biomarker?Lancet Respir Med20175974775928601554
   PubMed Web of Science ®Google Scholar
• PapiAKostikasKWedzichaJADual bronchodilation response by exacerbation history and eosinophilia in the FLAME studyAm J Respir Crit Care Med201819791223122629099609
   PubMed Web of Science ®Google Scholar
• RocheNChapmanKRVogelmeierCFBlood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. Data from the FLAME TrialAm J Respir Crit Care Med201719591189119728278391
   PubMed Web of Science ®Google Scholar
• GrunigGBaghdassarianAParkSHChallenges and current efforts in the development of biomarkers for chronic inflammatory and remodeling conditions of the lungsBiomark Insights201510Suppl 4597226917944
   PubMedGoogle Scholar
• NanniniLJLassersonTJPoolePCombined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20129CD00682922972099
   PubMed Web of Science ®Google Scholar
• RossiAvan der MolenTdel OlmoRINSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPDEur Respir J20144461548155625359348
   PubMed Web of Science ®Google Scholar
• ChoudhuryABDawsonCMKilvingtonHEWithdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trialRespir Res200789318162137
   PubMed Web of Science ®Google Scholar
• WoutersEFPostmaDSFokkensBWithdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trialThorax200560648048715923248
   PubMed Web of Science ®Google Scholar
• van der ValkPMonninkhofEvan der PalenJZielhuisGvan HerwaardenCEffect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE studyAm J Respir Crit Care Med2002166101358136312406823
   PubMed Web of Science ®Google Scholar
• O’BrienARusso-MagnoPKarkiAEffects of withdrawal of inhaled steroids in men with severe irreversible airflow obstructionAm J Respir Crit Care Med2001164336537111500334
   PubMed Web of Science ®Google Scholar
• VogelmeierCWorthHBuhlR“Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORDInt J Chron Obstruct Pulmon Dis20171248749428203072
   PubMed Web of Science ®Google Scholar
• RossiAGuerrieroMCorradoAOPTIMO/AIPO Study GroupWithdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)Respir Res2014157725005873
   PubMed Web of Science ®Google Scholar
• NadeemNJTaylorSJEldridgeSMWithdrawal of inhaled corticosteroids in individuals with COPD – a systematic review and comment on trial methodologyRespir Res20111210721838890
   PubMed Web of Science ®Google Scholar
• CalzettaLMateraMGBraidoFWithdrawal of inhaled corticosteroids in COPD: a meta-analysisPulm Pharmacol Ther20174514815828606478
   PubMed Web of Science ®Google Scholar
• JaradNAWedzichaJABurgePSCalverleyPMAn observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study GroupRespir Med199993316116610464871
   PubMed Web of Science ®Google Scholar
• SchermerTRHendriksAJChavannesNHProbability and determinants of relapse after discontinuation of inhaled corticosteroids in patients with COPD treated in general practicePrim Care Respir J2004131485516701637
   PubMedGoogle Scholar
• Al-KassimiFAAlhamadEHAl-HajjajMSAbrupt withdrawal of inhaled corticosteroids does not result in spirometric deterioration in chronic obstructive pulmonary disease: effect of phenotyping?Ann Thorac Med20127423824223189102
   PubMed Web of Science ®Google Scholar
• KunzLIZPostmaDSKloosterKRelapse in FEV1 decline after steroid withdrawal in COPDChest2015148238939625836351
   PubMed Web of Science ®Google Scholar
• BorrillZRoyKKolsumUSeretide withdrawal increases airway inflammation in moderate COPD patientsEur J Clin Pharmacol200965111165116619603154
   PubMed Web of Science ®Google Scholar
• KimSALeeJHKimEKOutcome of inhaler withdrawal in patients receiving triple therapy for COPDTuberc Respir Dis (Seoul)2016791223026770231
   PubMedGoogle Scholar
• KardosPVogelmeierCWorthHA two-year evaluation of the ‘real life’ impact of COPD on patients in Germany: the DACCORD observational studyRespir Med2017124576428284322
   PubMed Web of Science ®Google Scholar
• MagnussenHWatzHKirstenAStepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationaleRespir Med2014108459359924477080
   PubMed Web of Science ®Google Scholar